Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optivue Fusion
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Optivue Fusion is a commercially available, preservative-free artificial tear eye drop developed by Allergan. It is a combination drug containing 0.5% carboxymethylcellulose and 1% glycerin, primarily indicated for the short-term relief of dry eye disease symptoms by lowering tear film osmolarity.
- Brand names
- Optivue Fusion UDOptive Fusion UD
- Other names
- Optive Fusion UDOptive Fusion PFOptive Fusion Multi-Dose
02
Targets
CD44 (CD44 antigen)GLUT1 (Glucose transporter 1)
Beyond the preview
Go deeper on Optivue Fusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optivue Fusion.